Charlie's Holdings, Inc. Annual Report - How They Did This Year

I’m putting together a plain-English guide to help you understand how Charlie's Holdings, Inc. performed this year. My goal is to cut through the corporate jargon and give you the facts you need to decide if this company fits your portfolio.

1. What does this company do?

Charlie’s sells vaping products. They focus on two main areas: traditional nicotine liquids (like Pacha) and a newer line of "alternative" products called SBX, which uses a patented ingredient called Metatine™. They sell to over 3,000 specialty retailers, gas stations, and liquor stores across the U.S. By focusing on wholesale distribution, they keep costs low but rely heavily on their retail partners to keep their products on shelves.

2. The "Big Bet": Avoiding Regulation

The company’s strategy is to stay one step ahead of the FDA.

• The Metatine Loophole: Because their SBX line uses Metatine instead of tobacco-derived nicotine, they argue it falls outside the FDA’s reach. This allows them to sell flavored vapes in areas that have banned flavored nicotine.
• The Regulatory Tug-of-War: In late 2025, the FDA tried to block several core products. Charlie’s successfully challenged these orders in court, winning a temporary stay. This allows them to keep selling for now, but they are in a high-stakes game. A single court loss could permanently wipe out their main revenue sources.

3. Financial Health: Revenue is Up, but Cash is Burning

The 2025 numbers show a company growing fast, but it is costing them a fortune:

• Revenue Growth: They generated $20.9 million in revenue in 2025, up 168% from $7.8 million in 2024. The SBX line drove most of this growth.
• The Cash Burn: Operating expenses—like legal fees and marketing—outpaced sales. They burned through $6.3 million in cash this year, a 215% increase over 2024.
• The Funding Treadmill: As of February 2026, there are over 274 million shares outstanding. Because the company isn't profitable, they frequently issue more shares to pay the bills. For you, this means your ownership percentage is constantly being watered down.

4. Major Operational Risks

• No Manufacturing of Their Own: Charlie’s outsources all manufacturing. They have no control over production quality or speed. If a factory shuts down, they have no backup plan and will run out of inventory immediately.
• Key Person Risk: The company relies heavily on COO Ryan Stump and President Henry Sicignano III. There is no formal succession plan or insurance for these leaders. If either leaves, the company could lose its direction and investor confidence.
• Cybersecurity: The company relies on digital systems to manage 3,000+ accounts. A data breach or ransomware attack would freeze their ability to process orders and stop their revenue flow.

5. The Bottom Line

Charlie’s is a high-risk, speculative play. While they tripled their revenue in 2025, they are spending cash faster than ever. You are betting they can survive FDA battles and fix their cash-flow problems. Expect high volatility, as the company’s future depends on legal wins and the constant need to issue more shares.

Investor Checklist:

• Are you comfortable with legal risk? If the FDA wins in court, the company’s primary revenue stream could be shut down.
• Are you okay with dilution? The company frequently issues new shares to cover operating costs, which reduces the value of existing shares.
• Do you have a high risk tolerance? This is a volatile, speculative stock that is currently burning more cash than it generates.